Come and work with us! We're looking for a trailblazer nurse practitioner/ transitional nurse practitioner passionate about rural health and #Antimicrobialstewardship to join us in beautiful Hunter ...

Lecturer or Assistant / Associate / Full Professor - Academic Infectious Diseases Specialist

Despite known maternal, perinatal, and infant health risks of tuberculosis during pregnancy, global estimates of incidence remain scarce. Existing est…

Explore open-access tools that turn AMR data into visual insights and enable ethical data reuse, driving research and policy worldwide. Webinar: AMR tools and resources for health professionals and r...

Infections are prevalent during the first month of life and represent one of the leading causes of neonatal mortality worldwide (1). In 2017, an estimated 1.3 million cases of neonatal sepsis were rep...

Despite known maternal, perinatal, and infant health risks of tuberculosis during pregnancy, global estimates of incidence remain scarce. Existing est…

Early IV to oral transition improves antibiotic treatment safety across many serious infections. In a rural health system, implementation of the COPAT Tria

Tuberculous meningitis is often lethal, and many survivors have disabilities despite antimicrobial treatment and adjunctive glucocorticoid therapy. Standard-dose rifampin has limited central nervou...

As it enters its second year of life, CMI Communications (CMI Comms) is pleased to follow the excellent example of its sister journal, Clinical Microbiology and Infection [1], and launch its first editorial fellowship. CMI Comms is looking for early- and mid-career researchers and clinician-researchers to join us as we grow the journal and our podcast, Communicable.The fellowship will last 2 years and will include training at both the journal and the podcast.CMI Comms training:-In the first year, editorial fellows will shadow associate editors and the editor-in-chief, observing the editorial flow of manuscript review and the reasoning behind editorial decision making. Editorial fellows will attend editors’ meetings (hybrid) and participate actively in board discussions and policy-making.-In the second year, editorial fellows will handle submissions front-line, deciding whether to send the article for peer review, selecting peer reviewers, and reaching final decisions, all under the supervision of the associate editor and the editor-in-chief and in line with the journal’s overall aims and principles [2,3].-New ideas for the journal and its various projects will be welcome throughout. Fellows may be asked to write editorial notes describing new series or projects that will be launched at their suggestion [4].Communicable podcast training:-In the first 3 months, fellows will shadow the editors as they co-host, and Drs Hostettler and Huttner as they edit and produce, the episodes.-Thereafter, fellows will plan, co-host, edit, and produce episodes under the supervision of the editors, with minimal or maximal involvement according to their own interest.-Throughout, fellows may suggest topics, guests, and other ideas for Communicable, which, like CMI Comms, is open to innovation.The principal reason for this editorial fellowship is the desire to train and prepare the next generation in both traditional medical publishing and emerging media for science communication and dissemination. Yet, other reasons, like CMI’s, may be a bit ‘selfish’: we hope that the fellowship will both help us identify strong candidates for CMI Comms editorships down the road, and enrich us with the novel ideas and fresh vision of newcomers.Who should apply? We are looking for clinicians in residency or fellowship, or during the roughly 5 years following completion of residency or fellowship; for PhD students in the same timeframes; and/or for post-doctoral fellows [5]. If you are further out than 5 years from training, you should still apply if you believe you are early-career when it comes to medical editing and publishing.For clinicians, we are looking for people in the fields of clinical microbiology and infectious diseases, but clinicians with other recent training whose main research interest is clinical microbiology or infectious diseases are also welcome. For PhD students and post-doctoral fellows, we are looking for those whose main interest is infection, its spread, and how we prevent and deal with it: host (immunity), pathogen (pathogenicity and transmission), and prevention and antimicrobial strategies, whether they be pharmacologic or other.We would expect applicants to be first authors of at least five articles describing original research and published in peer-reviewed journals. Experience as a peer reviewer and/or editor, as well as recent or ongoing activities within the European Society of Clinical Microbiology and Infectious Diseases, would be an advantage.Please send your application by e-mail to Dr Kathryn Hostettler (cmicommunications@escmid.org), CMI Comms’ editorial manager. Tell us where you are in your career, your research interests, prior experience in medical editing, science podcasting, networking and communication, and anything else you would like us to know when considering your candidacy. Please attach a letter of recommendation relevant to this position, your curriculum vitae, and a list of publications. In addition, please include a one-page document sharing your ideas on how CMI Comms can be useful to people at all stages of their careers. Other suggestions on how to improve CMI Comms are also welcome. The deadline for applications is 15 September 2025. We will make our decision by 1 November 2025 and expect you to join us, if selected, on 1 January 2026.Editorial noteNot peer reviewed.

Antibiotics remain a mainstay of therapy for diabetic foot osteomyelitis (DFO), but optimal duration of therapy remains unclear.ObjectivesTo evaluate the effect of duration of antibiotic therapy on treatment success for DFO.Data SourcesMedline, EMBASE and Cochrane CENTRAL databases were utilized to search for eligible studies from inception to 31 December 2024.Study eligibility criteriaWe included studies that reported antibiotic therapy duration and treatment outcomes for treatment of DFO.ParticipantsPatients receiving antibiotic therapy for treatment of DFO.InterventionsAntibiotic therapyAssessment of risk of biasThe Joanna Briggs Institute critical appraisal tools were used.Methods of data synthesisRandom-effects meta-analysis was used to assess the pooled treatment success rates for ≤6 weeks and >6 weeks antibiotic therapy. Treatment success by treatment modality and study design were also assessed.ResultsThirty-three studies, including 6 RCTs and 27 observational cohorts were included in this review. The pooled treatment success rate was 74% (95% CI: 69%, 80%) for both patients receiving ≤6 weeks and >6 weeks antibiotic therapy. Included RCTs demonstrated pooled success rates of 65% (95% CI: 49%, 80%) and 74% (95%CI: 62%, 85%) for ≤6 weeks and >6 weeks antibiotics respectively. There was only minor difference between patients receiving antibiotic therapy alone (73%, 95% CI: 62%, 82%) versus combined antibiotics with surgical therapy (75%, 95% CI: 66%, 82%). Heterogeneity was high (I2 = 90%).ConclusionsAlthough treatment success rates were equivalent for varying durations of antibiotic therapy, high heterogeneity in study design makes these results difficult to translate to clinical practice. Standardizing study design for future research and allocating treatments by risk profile will be essential for improving understanding of DFO therapy.Graphical abstractDownload: Download high-res image (463KB)Download: Download full-size image